Acute phase response in bronchiectasis and bronchus carcinoma.

Area of Science:

• Clinical Medicine
• Biochemistry
• Immunology

Background:

• The acute phase response is a systemic reaction to tissue injury or inflammation.
• C-reactive protein (CRP) and serum amyloid-A protein (SAA) are key biomarkers of the acute phase response.
• Understanding the acute phase response is crucial in managing chronic respiratory diseases and neoplastic conditions.

Purpose of the Study:

• To measure the acute phase response in patients with bronchiectasis, emphysema, bronchus carcinoma, and benign space-occupying lesions.
• To evaluate the clinical significance of ongoing acute phase responses in patients with bronchiectasis.
• To assess the utility of CRP and SAA measurements in monitoring bronchus carcinoma.

Main Methods:

• Utilized sensitive immunoradiometric assays for quantifying C-reactive protein (CRP) and serum amyloid-A protein (SAA).
• Analyzed acute phase response markers in patient cohorts including bronchiectasis, emphysema, bronchus carcinoma, and benign lesions.
• Correlated biomarker levels with clinical status, including remission in bronchiectasis.

Main Results:

• A significant acute phase response was detected in some bronchiectasis patients, even when clinically in remission.
• The acute phase response in bronchiectasis may indicate a predisposition to reactive secondary amyloidosis.
• In bronchus carcinoma, infection-related inflammation often overrides neoplastic processes in initiating the acute phase response, limiting its use for tumor staging.

Conclusions:

• Elevated CRP and SAA levels in clinically stable bronchiectasis patients suggest a persistent inflammatory state with potential long-term complications like amyloidosis.
• The acute phase response is a complex indicator in bronchus carcinoma, often confounded by secondary infections.
• Sensitive assays for CRP and SAA are valuable tools for assessing inflammatory activity in various respiratory and neoplastic diseases.